NASDAQ | Warrant
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.
It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions.
The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jun 30, 21 | -0.46 | - |
| Mar 31, 21 | -0.44 | - |
| Dec 31, 20 | -0.20 | - |
| Sep 30, 20 | -0.20 | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 8.88 M Increased by +105.44% | -6.34 M Decreased by -147.16% | Decreased by -71.43% Decreased by -20.31% |
| Jun 30, 23 | 5.85 M Increased by +31.21% | -9.84 M Decreased by -239.22% | Decreased by -168.21% Decreased by -206.10% |
| Mar 31, 23 | 8.73 M Decreased by -4.74% | -7.48 M Increased by +48.45% | Decreased by -85.63% Increased by +45.88% |
| Dec 31, 22 | 10.14 M Increased by +10.65% | -2.79 M Increased by +80.80% | Decreased by -27.45% Increased by +82.65% |
| Sep 30, 22 | 4.32 M Decreased by -0.28% | -2.57 M Increased by +83.97% | Decreased by -59.37% Increased by +83.93% |
| Jun 30, 22 | 4.46 M Decreased by -23.88% | 7.07 M Increased by +293.01% | Increased by +158.54% Increased by +353.55% |
| Mar 31, 22 | 9.17 M Increased by +93.25% | -14.51 M Decreased by -310.44% | Decreased by -158.21% Decreased by -112.38% |
| Dec 31, 21 | 9.17 M Increased by +6.95% | -14.51 M Decreased by -7.70 K% | Decreased by -158.21% Decreased by -7.19 K% |